Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An inflammation-modulating ferroptotic nanoplatform for immune-compatible cancer therapy.

Journal of nanobiotechnology·2026
Same author

Deciphering the Heterogeneous Microenvironment of Head and Neck Squamous Cell Carcinoma Through an Integrated Immune Inflammation Framework.

International journal of genomics·2026
Same author

A Combined Posterior Stable Prosthesis and Medial Condylar Sliding Osteotomy Technique for Kashin-Beck Osteoarthritis.

Journal of visualized experiments : JoVE·2026
Same author

Integrative Genomic and Single-Cell Insights Into Efferocytosis-Mediated Immune Regulation in Clear Cell Renal Cell Carcinoma.

Mediators of inflammation·2026
Same author

Global research trends and foci of ablation therapies for liver tumours: a scientometric study.

Journal of gastrointestinal oncology·2026
Same author

ACACA modulates R-loop homeostasis to enhance lipid metabolism and microenvironmental interactions in ccRCC.

NPJ precision oncology·2026

Related Experiment Video

Updated: Jul 1, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

507

Second primary malignancy post immunotherapy: A case report of 2 cases.

Xian Miao1, Shu Dong2, Yuhua Tao1

  • 1Department of Oncology, Nantong Hospital Affiliated to Nanjing University of Chinese Medicine, Nantong, China.

Medicine
|March 8, 2024
PubMed
Summary

Second primary malignancies can occur during immune checkpoint inhibitor therapy. Continued immunotherapy and timely treatment of new cancers are crucial for patients, with careful monitoring essential.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Immune checkpoint inhibitors (ICIs) are effective first-line treatments for advanced cancers.
  • The impact of ICIs on second primary malignancies (SPMs) and associated practice patterns remain unclear.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

Related Experiment Videos

Last Updated: Jul 1, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

507
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K
  • Cases of SPM developing during immunotherapy are rarely reported.